THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER

The urgency of the problem of prostate cancer (PC) remains extremely high due to the continued growth of morbidity and mortality from this disease. Despite the introduction of diagnostics with the use of prostate specific antigen (PSA) and the increase in the number of cases of detection of localize...

Full description

Bibliographic Details
Main Authors: E. Yu. Safronova, A. A. Krasheninnikov, S. A. Sergienko, A. A. Kostin
Format: Article
Language:Russian
Published: QUASAR, LLC 2017-06-01
Series:Issledovaniâ i Praktika v Medicine
Subjects:
Online Access:https://www.rpmj.ru/rpmj/article/view/183
_version_ 1797874137678479360
author E. Yu. Safronova
A. A. Krasheninnikov
S. A. Sergienko
A. A. Kostin
author_facet E. Yu. Safronova
A. A. Krasheninnikov
S. A. Sergienko
A. A. Kostin
author_sort E. Yu. Safronova
collection DOAJ
description The urgency of the problem of prostate cancer (PC) remains extremely high due to the continued growth of morbidity and mortality from this disease. Despite the introduction of diagnostics with the use of prostate specific antigen (PSA) and the increase in the number of cases of detection of localized forms of the disease, frequency of detection in the primary treatment of patients with advanced and metastatic prostate cancer remains high. Therapy aimed at reducing testosterone levels in the body of the patient with metastatic prostate cancer is the gold standard of treatment, so surgical or pharmacological castration to reduce testosterone levels, are generally accepted methods of therapy. Hormone therapy (HT) using a pharmacological castration is the major and most commonly used method of treatment of patients with metastatic prostate cancer, the effectiveness of which is comparable with surgical castration. The article presents a review of studies that compared the effectiveness and side effects of HT with the use of surgical and medical castration, as well as the results of domestic studies evaluated the effectiveness of the application of the drug buserelin-domestic analogue of LHRH.
first_indexed 2024-04-10T01:26:02Z
format Article
id doaj.art-6e01dde38c124c739b0281c7b30b4d3c
institution Directory Open Access Journal
issn 2410-1893
language Russian
last_indexed 2024-04-10T01:26:02Z
publishDate 2017-06-01
publisher QUASAR, LLC
record_format Article
series Issledovaniâ i Praktika v Medicine
spelling doaj.art-6e01dde38c124c739b0281c7b30b4d3c2023-03-13T09:34:59ZrusQUASAR, LLCIssledovaniâ i Praktika v Medicine2410-18932017-06-0142232810.17709/2409-2231-2017-4-2-3143THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCERE. Yu. Safronova0A. A. Krasheninnikov1S. A. Sergienko2A. A. Kostin3Московский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииМосковский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииМосковский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииМосковский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииThe urgency of the problem of prostate cancer (PC) remains extremely high due to the continued growth of morbidity and mortality from this disease. Despite the introduction of diagnostics with the use of prostate specific antigen (PSA) and the increase in the number of cases of detection of localized forms of the disease, frequency of detection in the primary treatment of patients with advanced and metastatic prostate cancer remains high. Therapy aimed at reducing testosterone levels in the body of the patient with metastatic prostate cancer is the gold standard of treatment, so surgical or pharmacological castration to reduce testosterone levels, are generally accepted methods of therapy. Hormone therapy (HT) using a pharmacological castration is the major and most commonly used method of treatment of patients with metastatic prostate cancer, the effectiveness of which is comparable with surgical castration. The article presents a review of studies that compared the effectiveness and side effects of HT with the use of surgical and medical castration, as well as the results of domestic studies evaluated the effectiveness of the application of the drug buserelin-domestic analogue of LHRH.https://www.rpmj.ru/rpmj/article/view/183рак предстательной железыаналоги лютеинизирующего гормона рилизинг-гормонабусерелин-лонг
spellingShingle E. Yu. Safronova
A. A. Krasheninnikov
S. A. Sergienko
A. A. Kostin
THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
Issledovaniâ i Praktika v Medicine
рак предстательной железы
аналоги лютеинизирующего гормона рилизинг-гормона
бусерелин-лонг
title THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
title_full THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
title_fullStr THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
title_full_unstemmed THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
title_short THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
title_sort use of modern analogues of luteinizing hormone releasing hormone in the hormonal therapy in patients with prostate cancer
topic рак предстательной железы
аналоги лютеинизирующего гормона рилизинг-гормона
бусерелин-лонг
url https://www.rpmj.ru/rpmj/article/view/183
work_keys_str_mv AT eyusafronova theuseofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT aakrasheninnikov theuseofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT sasergienko theuseofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT aakostin theuseofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT eyusafronova useofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT aakrasheninnikov useofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT sasergienko useofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer
AT aakostin useofmodernanaloguesofluteinizinghormonereleasinghormoneinthehormonaltherapyinpatientswithprostatecancer